American Fusion Expands Scientific Advisory and Patent Portfolio as Texatron Testing Advances

American Fusion Inc. (OTC: AMFN) is broadening its scientific expertise and intellectual property as it accelerates testing of its Texatron Fusion Engine. The company has appointed Dr. Noah D’Amico, a physicist and engineer at Texas Tech University, as a Strategic Advisor, a move that aligns with its efforts to enhance diagnostic and engineering capabilities for its fusion program.

Dr. D’Amico’s background includes nuclear diagnostics, neutron detection, radiation measurement, vacuum-system design, and AI-assisted analysis of CR-39 nuclear particle tracks. He earned his Ph.D. in Physics from Texas Tech in 2026. His ongoing work at Texas Tech and BlankSlate Innovation will continue alongside his advisory role with American Fusion. The appointment is detailed in a recent announcement (https://nnw.fm/eA8ku).

In parallel, American Fusion has filed six additional U.S. patent applications, bringing its total to 82. This expansion of its IP portfolio is part of a broader strategy to protect its innovations in fusion energy technology.

The company has also initiated testing of its Texatron platform at Texas Tech University after completing initial laboratory preparations and verifying its remote ignition system. The next phase of testing will focus on subsystems including plasma and magnetic-field control, ignition, fuel delivery, and electronic components. These tests are critical to evaluating the feasibility and performance of the Texatron design.

The addition of Dr. D’Amico and the increased patent filings signal American Fusion’s commitment to advancing its fusion technology. By strengthening its scientific advisory team and securing intellectual property, the company aims to solidify its position in the emerging fusion energy sector. The successful testing of the Texatron could have significant implications for clean energy generation, as fusion has the potential to provide a nearly limitless and environmentally friendly power source.

As American Fusion progresses through its testing phases, the company continues to build a foundation for commercial viability. The integration of advanced diagnostics and AI-based analysis, as exemplified by Dr. D’Amico’s expertise, is essential for optimizing the fusion process and overcoming technical challenges.

Investors and industry observers are watching closely as American Fusion moves from laboratory preparations to active testing. The outcome of these tests will be instrumental in determining the next steps for the Texatron program and the company’s overall trajectory.

For more information on American Fusion’s latest developments, visit the company’s newsroom at https://nnw.fm/AMFN.